Skip to main navigation Skip to search Skip to main content

Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need

  • Neil Cherian
  • , Alison Bettis
  • , Arminder Deol
  • , Arun Kumar
  • , Jose Luis Di Fabio
  • , Amol Chaudhari
  • , Solomon Yimer
  • , Raafat Fahim
  • , Timothy Endy
  • Coalition for Epidemics Preparedness Innovations

Research output: Contribution to journal › Review article › peer-review

41 Scopus citations

Abstract

Chikungunya is an arboviral disease caused by the chikungunya virus (CHIKV) afflicting tropical and sub-tropical countries worldwide. It has been identified as a priority pathogen by the Coalition for Epidemics Preparedness Innovations (CEPI) and as an emerging infectious disease (EID) necessitating further action as soon as possible by the World Health Organization (WHO). Recent studies suggest that disability-adjusted life years (DALYs) due to CHIKV infection are as high as 106,089 DALYs lost globally. Significant progress has been made in the development of several vaccines, aimed at preventing CHIKV infections. This perspective article summarizes CEPI’s efforts and strategic considerations for developing a CHIKV vaccine and ensuring equitable access for CHIKV endemic countries.

Original languageEnglish
Article number123
Journalnpj Vaccines
Volume8
Issue number1
DOIs
StatePublished - Dec 2023

Fingerprint

Dive into the research topics of 'Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need'. Together they form a unique fingerprint.

Cite this